pharma, deals, Biotech
$80M Payday for Synta
Rebecca Zacks 12/5/07
GlaxoSmithKline has written Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) a check for $80 million. The payment is the first installment under a cancer-drug development agreement that could ultimately be worth $1.1 billion for the Lexington firm.
